Epac-inhibitors: facts and artefacts

Area of Science:

• Molecular Biology
• Pharmacology
• Biophysics

Background:

• Cyclic adenosine monophosphate (cAMP) is a crucial second messenger regulating diverse physiological processes in mammals.
• cAMP signaling pathways involve protein kinase A (PKA), Exchange proteins directly activated by cAMP (Epac), and ion channels.
• Selective pharmacological targeting of cAMP pathways, particularly Epac, is of significant medical interest, yet selective Epac inhibitors were historically lacking.

Purpose of the Study:

• To investigate the pharmacological action and selectivity of novel Epac inhibitors using biophysical methods.
• To validate the specificity of ESI-05, ESI-09, HJC0197, and Brefeldin A concerning Epac inhibition.

Main Methods:

• Biophysical analysis was employed to assess the interaction of novel compounds with Epac.
• The study focused on evaluating the selective inhibitory potential of ESI-05, ESI-09, HJC0197, and Brefeldin A.

Main Results:

• ESI-05 was confirmed as a selective inhibitor specifically targeting Epac2.
• Brefeldin A demonstrated no direct inhibitory effect on Epac.
• ESI-09 and HJC0197 were identified as non-selective compounds with general protein-denaturing properties, lacking Epac specificity.

Conclusions:

• The findings validate ESI-05 as a selective Epac2 inhibitor, providing a valuable tool for research.
• The study highlights the importance of rigorous biophysical validation to distinguish selective inhibitors from general protein-damaging agents.
• The lack of selectivity for ESI-09 and HJC0197 underscores the challenges in developing specific Epac inhibitors.